$35
Supernus Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. Supernus Pharmaceuticals shares (SUPN) are listed on the NASDAQ and all prices are listed in US Dollars. Supernus Pharmaceuticals employs 652 staff and has a trailing 12-month revenue of around $630.2 million.
Our top picks for where to buy Supernus Pharmaceuticals stock
How to buy Supernus Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – SUPN. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Supernus Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Supernus Pharmaceuticals stock price (NASDAQ: SUPN)
Use our graph to track the performance of SUPN stocks over time.Supernus Pharmaceuticals shares at a glance
Latest market close | $34.71 |
---|---|
52-week range | $21.99 - $35.44 |
50-day moving average | $30.32 |
200-day moving average | $29.43 |
Wall St. target price | $40.50 |
PE ratio | 390.6667 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $0.09 |
Is it a good time to buy Supernus Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Supernus Pharmaceuticals price performance over time
Historical closes compared with the close of $34.71 from 2024-09-03
1 week (2024-08-29) | -0.83% |
---|---|
1 month (2024-08-05) | 24.32% |
3 months (2024-06-05) | 26.03% |
6 months (2024-03-05) | 14.37% |
1 year (2023-09-05) | 9.29% |
---|---|
2 years (2022-09-02) | 0.93% |
3 years (2021-09-03) | 26.40% |
5 years (2019-09-05) | 25.72% |
Is Supernus Pharmaceuticals stock undervalued or overvalued?
Valuing Supernus Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Supernus Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Supernus Pharmaceuticals's P/E ratio
Supernus Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 391x. In other words, Supernus Pharmaceuticals shares trade at around 391x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Supernus Pharmaceuticals's PEG ratio
Supernus Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.47. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Supernus Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Supernus Pharmaceuticals's EBITDA
Supernus Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $125.6 million.
The EBITDA is a measure of a Supernus Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Supernus Pharmaceuticals financials
Revenue TTM | $630.2 million |
---|---|
Operating margin TTM | 10.82% |
Gross profit TTM | $580 million |
Return on assets TTM | 1.95% |
Return on equity TTM | 0.56% |
Profit margin | 0.83% |
Book value | $17.39 |
Market Capitalization | $1.9 billion |
TTM: trailing 12 months
Supernus Pharmaceuticals share dividends
We're not expecting Supernus Pharmaceuticals to pay a dividend over the next 12 months.
Supernus Pharmaceuticals share price volatility
Over the last 12 months, Supernus Pharmaceuticals's shares have ranged in value from as little as $21.99 up to $35.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Supernus Pharmaceuticals's is 0.886. This would suggest that Supernus Pharmaceuticals's shares are less volatile than average (for this exchange).
Supernus Pharmaceuticals overview
Supernus Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc.
Frequently asked questions
What percentage of Supernus Pharmaceuticals is owned by insiders or institutions?Currently 5.009% of Supernus Pharmaceuticals shares are held by insiders and 109.799% by institutions. How many people work for Supernus Pharmaceuticals?
Latest data suggests 652 work at Supernus Pharmaceuticals. When does the fiscal year end for Supernus Pharmaceuticals?
Supernus Pharmaceuticals's fiscal year ends in December. Where is Supernus Pharmaceuticals based?
Supernus Pharmaceuticals's address is: 9715 Key West Avenue, Rockville, MD, United States, 20850 What is Supernus Pharmaceuticals's ISIN number?
Supernus Pharmaceuticals's international securities identification number is: US8684591089 What is Supernus Pharmaceuticals's CUSIP number?
Supernus Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 868459108
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question